Dymista: new intranasal rhinitis treatment

The nasal spray Dymista is now available for the treatment of perennial and seasonal allergic rhinitis.

Dymista is licensed for use in adults and children 12 years and older at a dose of one spray per nostril twice daily
Dymista is licensed for use in adults and children 12 years and older at a dose of one spray per nostril twice daily


Dymista is a novel combination of two drugs in a nasal spray formulation: fluticasone propionate, a synthetic glucocorticoid, and azelastine, a potent selective H1-antagonist.1


Seasonal allergic rhinitis

The efficacy and safety of the fluticasone/azelastine combination spray in moderate to severe seasonal allergic rhinitis were assessed in 2 randomised, double-blind studies of similar design (n=610 and n=3398). Patients were randomised for twice-daily treatment with the combination nasal spray, fluticasone nasal spray, azelastine nasal spray or placebo (vehicle) for 14 days.2,3

In both studies, the reduction from baseline in total nasal symptom score (comprising nasal congestion, runny nose, itchy nose and sneezing) was significantly greater for the combination spray than for either agent used alone or placebo.2,3

Chronic rhinitis

A further study (n=612) evaluated the safety and efficacy of fluticasone/azelastine in patients with chronic rhinitis (including perennial allergic rhinitis and non-allergic rhinitis) over 12 months using fluticasone as an active control.4

The combination spray resulted in significantly greater nasal symptom relief than fluticasone monotherapy up to week 28. Treatment differences remained consistent to week 52 but significance could not be established owing to decreasing sample sizes.4

Adverse effect profile

The combination spray was well tolerated, with the most commonly reported adverse effects being epistaxis, dysgeusia, dysosmia and headache.1,3


  1. Dymista Summary of Product Characteristics, January 2013.
  2. Hampel F et al. Ann Allergy Asthma Immunol  2010; 105: 168–173.
  3. Carr W et al. J Allergy Clin Immunol 2012; 129: 12829.
  4. Price D et al.  Poster presented at Congress of European Academy of Allergy and Clinical Immunology. Geneva, Switzerland. June 2012. P32-872.

View Dymista drug record

Further information: Meda

Follow MIMS on Twitter



Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more